Home » Healthcare » Pharmaceuticals » Specialty Generics Market

Specialty Generics Market By Drug Class (Oncology Drugs, Injectable Drugs, Biologics, Complex Formulations, Respiratory Drugs, Dermatology Drugs, Ophthalmology Drugs, Others) By Route of Administration (Oral, Injectable, Topical, Ocular, Inhalable) – Growth, Share, Opportunities & Competitive Analysis, 2018 – 2028

Summary
Table Of Content

Market Insights

The global demand for specialty generics was valued at USD 69158.6 Million in 2022 and is expected to reach USD 151513.1 Million in 2030, growing at a CAGR of 10.3% between 2023 and 2030.
The injectable drugs segment is the market leader by drug class, accounting for more than 30% of total value in 2022, while the oncology drugs segment is estimated to grow rapidly in the projection period.
The oral route of administration category is expected to expand quickly in the forecast period, while the injectable segment has the greatest market share in 2022.
The autoimmune diseases segment dominates the global need for specialty generics, accounting for more than 28% in 2022 and is predicted to expand at a high CAGR.
The hospitals and clinics category dominated the market with 35% of the total revenue share by end-users. In contrast, the retail pharmacies category will expand fastest over the projected time frame.
North America is driving the expansion of the specialized generics business, accounting for more than one-third of the market in 2022, while Asia Pacific and Europe account for just under 54% of the market in 2022. In 2022, Europe had a market revenue share of more than 20%.
Specialty generics cover a wide range of therapeutic areas, including biosimilars, oncology, dermatology, ophthalmology, neurology, and more, making it a diverse and dynamic market.
Specialty generics often involve complex drug formulations, such as injectables, inhalable, and transdermal patches, which require specialized manufacturing capabilities.
Specialty generics play a key role in improving patient access to essential medications, particularly in cases where brand-name specialty drugs are expensive or unavailable.
The specialty generics market is highly dynamic, with opportunities evolving based on factors like new drug approvals, patent expirations, and changing healthcare policies.

Executive Summary

Market Definition

The specialty generics market encompasses the production and distribution of generic versions of high-complexity medications used to treat a diverse array of medical conditions, including rare diseases, oncology, autoimmune disorders, dermatology, and ophthalmology. These drugs are often characterized by their intricate formulations, such as injectables, biologics, and biosimilars. They are essential for offering cost-effective alternatives to brand-name specialty medications, thereby enhancing patient access to vital treatments for complex or chronic health conditions.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global specialty generics market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 10.3% between 2023 and 2030. The market was valued at USD 69158.6 million in 2022 and is expected to reach USD 151513.1 million in 2030.

Specialty generics are generic copies of expensive brand-name specialty medications. These drugs are widely used to treat complex, chronic illnesses like cancer, rheumatoid arthritis, multiple sclerosis (MS), and HIV. They differ from ordinary generics in that they are often biologic-based, require particular handling and administration, are frequently injectables, and are commonly provided through limited networks. The production of specialized generics involves certain limitations due to the complicated nature of the molecules involved and the complex procedures employed in their manufacture. Thus, regulatory processes for their approval may be stricter than for typical generic medications. Furthermore, specialty generics have enormous potential in the healthcare industry. They provide patients with access to critical treatments at a lower cost while also reducing the financial load on healthcare systems.

The rising prevalence of complex chronic diseases such as hepatitis C, as well as the increasing acceptance of specialty generic pharmaceuticals for their treatment, is a major driver of market expansion. For example, the number of persons suffering from MS globally increased from 2.3 million in 2013 to 2.8 million in 2020, according to data provided by the Multiple Sclerosis International Federation (MSIF) in 2020. This figure is anticipated to rise in the future years. Other factors driving the robust growth of the global market include the expanding generic population and the pending patent expirations of a number of branded specialty medications.

Segmentation by Drug Class

The oncology drugs segment is anticipated to demonstrate the highest CAGR in the forecast period, driven by the growing incidence of cancer worldwide and the need for cost-effective treatment options.
Injectable drugs currently dominate the market share, comprising over 30% in 2022, owing to the prevalence of complex and high-cost injectable specialty medications.

Segmentation by Route of Administration

The oral segment is projected to register the highest CAGR, primarily due to the convenience and patient preference associated with oral administration.
Injectable drugs lead the market, with a share of over 28% in 2022, owing to the precise and effective delivery of specialty medications through this route.

Segmentation by Disease Area

Autoimmune diseases constitute the dominant category, accounting for more than 30% of the global specialty generics market demand in 2022. This is attributed to the surging prevalence of autoimmune disorders and the need for affordable treatments.
The cancer and respiratory diseases segment fulfills the remaining specialty generics market needs, with cancer treatments benefiting from the oncology drug segment’s growth.

Segmentation by End-Users

Retail pharmacies are projected to exhibit the highest CAGR due to their accessibility and role in providing specialty generics to a broader patient base.
Hospitals and clinics currently lead the market share, with over 35% in 2022, owing to the administration of specialty medications in clinical settings.

Segmentation by Region

North America’s robust healthcare infrastructure and research capabilities make it a highly lucrative region, holding over one-third of the global specialty generics market share in 2022.
Asia Pacific and Europe collectively contribute to nearly 54% of the market share, with the Asia Pacific region displaying significant growth potential due to its expanding middle-class population and increasing healthcare access.
Europe’s substantial share of over 20% in the same year reflects its established medical facilities and robust market presence.
The rest of the world, encompassing regions like Latin America, the Middle East, and Africa, contributes to the remaining demand for specialty generics, offering untapped growth opportunities in emerging markets.

North America dominates the global specialty generics market. The region has a well-established pharmaceutical industry, extensive healthcare infrastructure, and a higher prevalence of chronic diseases, all contributing to a robust demand for specialty generics. Additionally, the United States, in particular, has a favorable regulatory environment for generic drugs and biosimilars, with well-defined pathways for approval. The presence of major pharmaceutical companies, research and development capabilities, and a strong emphasis on innovation further strengthens North America’s position in the specialty generics industry. Moreover, a large patient population, a culture of cost containment in healthcare, and well-structured reimbursement systems make North America an attractive market for specialty generics manufacturers seeking growth and profitability.

Over the projection period, the Asia Pacific is estimated to be the fastest-growing market for specialty generics. The region is experiencing rapid economic growth, leading to an expanding middle-class population with increased healthcare access and affordability. The prevalence of chronic diseases is also on the rise in Asia Pacific, leading to a higher demand for specialty medications. Besides, governments in the region are increasingly focused on healthcare reform and cost containment, driving the adoption of cost-effective specialty generics. Additionally, advancements in biopharmaceutical manufacturing and the adoption of biosimilars are gaining traction in the Asia Pacific, providing substantial growth opportunities.

Key Highlights of the Report

The global specialty generics market is segmented by drug class, route of administration, disease area, end-users, and region. The oncology drug class segment, particularly biosimilars, is expected to exhibit substantial growth owing to the expanding prevalence of cancer and the demand for cost-effective treatment options. Injectable drugs currently dominate the market share, primarily due to the complexity and high cost of injectable specialty medications. However, the oral route of administration segment is projected to register the highest growth rate, reflecting patient preferences for convenient oral administration methods. Autoimmune diseases constitute the dominant disease area, driven by the rising incidence of autoimmune disorders and the need for affordable treatments. Additionally, the market caters to cancer and respiratory diseases, fulfilling specialized medication requirements. Among end-users, hospitals & clinics currently dominate the market revenue share.

The increasing prevalence of chronic conditions such as cancer, diabetes, and cardiovascular disease has increased the demand for specialty generics. These medications are frequently used to treat complex illnesses that necessitate specialized formulas, and they provide a cost-effective alternative to branded drugs. Rising healthcare expenditures are driving up demand for cost-effective alternatives, such as specialized generics. These medications offer significant cost reductions over branded drugs, making them an appealing option for both patients and healthcare professionals. Technology improvements are allowing for the development of more complex and specialized formulations, which is fueling the growth of the specialty generics market. New drug delivery technologies and adaptable formulations are broadening the spectrum of therapy options available to patients.

North America holds a substantial share of the market due to its strong healthcare infrastructure, extensive research capabilities, and high demand for specialty generics. Meanwhile, the Asia Pacific and Europe collectively contribute significantly to the market, with the Asia Pacific region showing considerable growth potential due to expanding healthcare access and a burgeoning middle-class population.

What Are The Main Drivers Of The Global Specialty Generics Market?

The main drivers of the global specialty generics market include the escalating prevalence of chronic diseases, an aging population in many regions, and the growing demand for cost-effective alternatives to specialty brand-name drugs, particularly as patents expire. Additionally, the rise of biosimilars, advancements in biopharmaceuticals, and the need for affordable treatments for complex and rare medical conditions are fueling market growth. Moreover, healthcare cost-containment efforts, the expansion of healthcare access in emerging markets, and the emphasis on personalized therapies are further propelling the specialty generics sector’s growth, making it a dynamic and essential component of the pharmaceutical industry.

What Are The Major Challenges Faced By The Global Specialty Generics Market?

The global specialty generics market faces several major challenges, including stringent regulatory requirements and lengthy approval processes, especially for biosimilars, which can be resource-intensive and time-consuming. Besides, intellectual property disputes and legal battles with originator companies can pose significant barriers to market entry. Pricing pressures from healthcare payers and governments, as well as market fragmentation with numerous players, intensify competition and can impact profitability. Moreover, supply chain complexities, particularly for temperature-sensitive drugs, and market access hurdles in various regions add to the complexity of operating in this specialized pharmaceutical sector.

What Are The Growth Opportunities In The Global Specialty Generics Market?

The increasing demand for affordable alternatives to high-cost specialty drugs, coupled with the expiration of patents for brand-name medications, creates a conducive environment for market expansion. Rapid advancements in biopharmaceuticals, including biosimilars and complex formulations, present substantial growth potential. The focus on rare diseases, personalized therapies, and expanded access to healthcare in emerging markets further broaden the scope for specialty generics. Companies investing in research and development, market access strategies, and global expansion stand to benefit from this dynamic market as it continues to evolve and meet the needs of patients worldwide.

Market Drivers

Several factors drive the global specialty generics market. The following are the key drivers of the global specialty generics market:

Expanding Demand for Affordable Medications

One of the primary drivers of the global specialty generics market is the increasing demand for affordable alternatives to high-cost specialty brand-name drugs. As the prevalence of chronic diseases rises, especially among aging populations in many regions, the cost burden on healthcare systems and patients escalates. The rising global prevalence of many life-threatening conditions, such as multiple sclerosis, cancer, and HIV, is expected to increase the uptake of specialty pharmaceuticals. As per the World Health Organisation (WHO) report 2022, over 58 million individuals worldwide have chronic hepatitis C virus infection, and nearly 1.5 million people are impacted by this infection each year. Also, according to data published by the Global RA Network in 2021, almost 350 million individuals globally have arthritis, and its prevalence is predicted to continue to increase in the coming years.

Specialty generics offer a cost-effective solution, providing access to critical medications at a fraction of the price of their branded counterparts. This demand for cost containment and greater access to essential treatments is propelling the growth of specialty generics, particularly in therapeutic areas such as oncology, autoimmune diseases, and rare conditions.

Market Restraints

The global specialty generics market faces challenges that may hinder its growth. These include the following:

Stringent Regulatory Requirements and Approval Processes

A key restraint in the specialty generics market is the extensive and rigorous regulatory requirements and approval processes, particularly for biosimilars and other complex formulations. Regulatory agencies worldwide, such as the U.S. FDA and the EMA (European Medicines Agency), impose stringent standards to ensure the safety, quality, and efficacy of specialty generic products. These requirements demand extensive preclinical and clinical studies, analytical data, and comparability assessments with reference products. Navigating these complex regulatory pathways can be resource-intensive, time-consuming, and costly for manufacturers, leading to delays in market entry and substantial investments in research and development.

Opportunities

The global specialty generics market offers significant growth opportunities. These include the following:

Emerging Focus on Rare Diseases and Orphan Drugs

The growing emphasis on specialty generics for rare diseases and orphan drugs offers a major opportunity for manufacturers. Rare diseases often have limited treatment options, and specialty generics can provide affordable alternatives for patients who would otherwise face high costs for life-saving medications. Moreover, regulatory incentives, such as orphan drug designations and extended market exclusivity periods, can encourage the development of specialty generics in this segment. With the potential for high margins and unmet medical needs, manufacturers can target rare disease therapies as a strategic growth opportunity within the specialty generics market, benefiting both patients and their bottom line.

Competitive Landscape

Key Players

The global specialty generics market is characterized by intense competition, with several established and emerging players vying for market share. The following are some of the top market players and their market shares:

Teva Pharmaceuticals Industries Ltd
Novartis AG
Bausch Health Companies Inc
Endo Pharmaceuticals Inc
Viatris Inc
Fresenius Kabi Brasil Ltd
STADA Arzneimittel AG
Apotex Corp.
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Sun Pharmaceutical Industries Ltd
Others

These companies are diversifying their product portfolios to include a wide range of specialty generic drugs, encompassing biosimilars, complex injectables, and other high-complexity formulations. They are also actively engaged in forming strategic partnerships, distribution agreements, and alliances to enhance their market reach and gain a competitive advantage. Many other companies are directing their efforts toward the development of specialty generics for rare diseases, offering potential high margins and addressing unmet medical needs.

Robust supply chain management, especially for temperature-sensitive biologics, remains pivotal to ensuring product availability and quality. The competitive landscape is also influenced by ongoing patent disputes and legal challenges from originator companies, requiring a specialized approach to intellectual property management.

In March 2022, Nevakar Injectables Inc., a biopharmaceutical firm producing numerous sterile injectable solutions for use in ambulatory and critical care settings, announced its ready-to-use Ephedrine Sulphate Injection, which comes in a 10mL vial and is pre-diluted to a 5mg/mL concentration.

In February 2022, Dr. Reddy’s Laboratories Ltd introduced the generic version of Par Pharmaceutical’s VASOSTRICT (vasopressin injectable, USP) Vials, which has been approved for sale in the U.S. market by the Food & Drug Administration (FDA).

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The global specialty generics market is experiencing robust growth, driven by the expanding prevalence of chronic diseases, the need for cost-effective medications, and the expansion of biopharmaceuticals, including biosimilars.
Market segmented by drug class, route of administration, disease area, end-users, and region.
Oncology drugs, particularly biosimilars, are projected to exhibit the highest growth rate, reflecting the rising incidence of cancer and the demand for affordable cancer treatment.
Injectable drugs dominate the market share, primarily due to the complex and high-cost nature of injectable specialty medications.
Oral specialty generics are gaining traction, driven by patient preferences for convenient administration methods.
Autoimmune diseases represent the dominant disease area, with a high demand for affordable treatments.
Retail pharmacies are expected to witness the highest growth rate among end-users, while hospitals and clinics currently lead the market share.
Regulatory requirements, intellectual property challenges, and legal disputes remain key challenges in this dynamic market.

Future Outlook

The market for antifungal drugs used in specialty generics is likely to experience robust growth owing to the rising number of immunocompromised patients and the persistent threat of fungal infections.
Patient demand for specialty generics is increasing as they offer affordable access to critical medications, especially in the treatment of complex and chronic disorders.
Advances in biopharmaceuticals are driving the need for biosimilars and specialty generic versions of these high-cost drugs.
Specialty generics for rare diseases are gaining wider attention, given the potential for high margins and the unmet medical needs in this area.

Segmentation

By Drug Class
- Oncology Drugs
- Injectable Drugs
- Biologics
- Complex Formulations
- Respiratory Drugs
- Dermatology Drugs
- Ophthalmology Drugs
- Others
By Route of Administration
- Oral
- Injectable
- Topical
- Ocular
- Inhalable
By Disease Area
- Cancer
- Autoimmune Diseases
- Respiratory Diseases
- Dermatological Conditions
- Ophthalmic Disorders
- Others
By End-Users
- Hospitals and Clinics
- Retail Pharmacies
- Specialty Pharmacies
- Online Pharmacies
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

Several adjacent markets have high revenue growth opportunities in the specialty generics market. The key adjacent markets for specialty generics market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Specialty Generics Market

2.1.1. Global Specialty Generics Market, By Drug Class

2.1.2. Global Specialty Generics Market, By Route of Administration

2.1.3. Global Specialty Generics Market, By Disease Area

2.1.4. Global Specialty Generics Market, By End-Users

2.1.5. Global Specialty Generics Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Specialty Generics Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Specialty Generics Market Drivers

3.2.2. Specialty Generics Market Restraints

3.2.3. Specialty Generics Market Opportunities

3.2.4. Major Specialty Generics Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Drug Class

3.5.2. Route of Administration

3.5.3. Disease Area

3.5.4. End-Users

3.5.5. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Specialty Generics Market: Company Market Share, Value 2022

4.1.2. Global Specialty Generics Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Specialty Generics Market: Top 3 Company Market Share, Value 2022

4.2. Global Specialty Generics Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Specialty Generics Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Specialty Generics Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Specialty Generics Market, By Drug Class

8.1. Global Specialty Generics Market Overview, by Drug Class

8.1.1. Global Specialty Generics Market Revenue Share, By Drug Class, 2022 Vs 2030 (in %)

8.2. Oncology Drugs

8.2.1. Global Specialty Generics Market, By Oncology Drugs, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Oncology Drugs

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Injectable Drugs

8.3.1. Global Specialty Generics Market, By Injectable Drugs, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Injectable Drugs

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Biologics

8.4.1. Global Specialty Generics Market, By Biologics, By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for Biologics

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Complex Formulations

8.5.1. Global Specialty Generics Market, By Complex Formulations, By Region, 2017-2030 (US$ Mn)

8.5.2. Market Dynamics for Complex Formulations

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

8.6. Respiratory Drugs

8.6.1. Global Specialty Generics Market, By Respiratory Drugs, By Region, 2017-2030 (US$ Mn)

8.6.2. Market Dynamics for Respiratory Drugs

8.6.2.1. Drivers

8.6.2.2. Restraints

8.6.2.3. Opportunities

8.6.2.4. Trends

8.7. Dermatology Drugs

8.7.1. Global Specialty Generics Market, By Dermatology Drugs, By Region, 2017-2030 (US$ Mn)

8.7.2. Market Dynamics for Dermatology Drugs

8.7.2.1. Drivers

8.7.2.2. Restraints

8.7.2.3. Opportunities

8.7.2.4. Trends

8.8. Ophthalmology Drugs

8.8.1. Global Specialty Generics Market, By Ophthalmology Drugs, By Region, 2017-2030 (US$ Mn)

8.8.2. Market Dynamics for Ophthalmology Drugs

8.8.2.1. Drivers

8.8.2.2. Restraints

8.8.2.3. Opportunities

8.8.2.4. Trends

8.9. Others

8.9.1. Global Specialty Generics Market, By Others, By Region, 2017-2030 (US$ Mn)

8.9.2. Market Dynamics for Others

8.9.2.1. Drivers

8.9.2.2. Restraints

8.9.2.3. Opportunities

8.9.2.4. Trends

9. Global Specialty Generics Market, By Route of Administration

9.1. Global Specialty Generics Market Overview, by Route of Administration

9.1.1. Global Specialty Generics Market Revenue Share, By Route of Administration, 2022 Vs 2030 (in %)

9.2. Oral

9.2.1. Global Specialty Generics Market, By Oral, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Oral

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Injectable

9.3.1. Global Specialty Generics Market, By Injectable, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Injectable

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Topical

9.4.1. Global Specialty Generics Market, By Topical, By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Topical

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

9.5. Ocular

9.5.1. Global Specialty Generics Market, By Ocular, By Region, 2017-2030 (US$ Mn)

9.5.2. Market Dynamics for Ocular

9.5.2.1. Drivers

9.5.2.2. Restraints

9.5.2.3. Opportunities

9.5.2.4. Trends

9.6. Inhalable

9.6.1. Global Specialty Generics Market, By Inhalable, By Region, 2017-2030 (US$ Mn)

9.6.2. Market Dynamics for Inhalable

9.6.2.1. Drivers

9.6.2.2. Restraints

9.6.2.3. Opportunities

9.6.2.4. Trends

10. Global Specialty Generics Market, By Disease Area

10.1. Global Specialty Generics Market Overview, by Disease Area

10.1.1. Global Specialty Generics Market Revenue Share, By Disease Area, 2022 Vs 2030 (in %)

10.2. Cancer

10.2.1. Global Specialty Generics Market, By Cancer, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Cancer

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Autoimmune Diseases

10.3.1. Global Specialty Generics Market, By Autoimmune Diseases, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Autoimmune Diseases

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Respiratory Diseases

10.4.1. Global Specialty Generics Market, By Respiratory Diseases, By Region, 2017-2030 (US$ Mn)

10.4.2. Market Dynamics for Respiratory Diseases

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

10.5. Dermatological Conditions

10.5.1. Global Specialty Generics Market, By Dermatological Conditions, By Region, 2017-2030 (US$ Mn)

10.5.2. Market Dynamics for Dermatological Conditions

10.5.2.1. Drivers

10.5.2.2. Restraints

10.5.2.3. Opportunities

10.5.2.4. Trends

10.6. Ophthalmic Disorders

10.6.1. Global Specialty Generics Market, By Ophthalmic Disorders, By Region, 2017-2030 (US$ Mn)

10.6.2. Market Dynamics for Ophthalmic Disorders

10.6.2.1. Drivers

10.6.2.2. Restraints

10.6.2.3. Opportunities

10.6.2.4. Trends

10.7. Others

10.7.1. Global Specialty Generics Market, By Others, By Region, 2017-2030 (US$ Mn)

10.7.2. Market Dynamics for Others

10.7.2.1. Drivers

10.7.2.2. Restraints

10.7.2.3. Opportunities

10.7.2.4. Trends

11. Global Specialty Generics Market, By End-Users

11.1. Global Specialty Generics Market Overview, by End-Users

11.1.1. Global Specialty Generics Market Revenue Share, By End-Users, 2022 Vs 2030 (in %)

11.2. Hospitals and Clinics

11.2.1. Global Specialty Generics Market, By Hospitals and Clinics, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Hospitals and Clinics

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Retail Pharmacies

11.3.1. Global Specialty Generics Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Retail Pharmacies

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

11.4. Specialty Pharmacies

11.4.1. Global Specialty Generics Market, By Specialty Pharmacies, By Region, 2017-2030 (US$ Mn)

11.4.2. Market Dynamics for Specialty Pharmacies

11.4.2.1. Drivers

11.4.2.2. Restraints

11.4.2.3. Opportunities

11.4.2.4. Trends

11.5. Online Pharmacies

11.5.1. Global Specialty Generics Market, By Online Pharmacies, By Region, 2017-2030 (US$ Mn)

11.5.2. Market Dynamics for Online Pharmacies

11.5.2.1. Drivers

11.5.2.2. Restraints

11.5.2.3. Opportunities

11.5.2.4. Trends

12. Global Specialty Generics Market, By Region

12.1. Global Specialty Generics Market Overview, by Region

12.1.1. Global Specialty Generics Market, By Region, 2022 vs 2030 (in%)

12.2. Drug Class

12.2.1. Global Specialty Generics Market, By Drug Class, 2017-2030 (US$ Mn)

12.3. Route of Administration

12.3.1. Global Specialty Generics Market, By Route of Administration, 2017-2030 (US$ Mn)

12.4. Disease Area

12.4.1. Global Specialty Generics Market, By Disease Area, 2017-2030 (US$ Mn)

12.5. End-Users

12.5.1. Global Specialty Generics Market, By End-Users, 2017-2030 (US$ Mn)

13. North America Specialty Generics Market Analysis

13.1. Overview

13.1.1. Market Dynamics for North America

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. North America Specialty Generics Market, by Drug Class, 2017-2030(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. North America Specialty Generics Market, by Route of Administration, 2017-2030(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. North America Specialty Generics Market, by Disease Area, 2017-2030(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. North America Specialty Generics Market, by End-Users, 2017-2030(US$ Mn)

13.5.1. Overview

13.5.2. SRC Analysis

13.6. North America Specialty Generics Market, by Country, 2017-2030 (US$ Mn)

13.6.1. North America Specialty Generics Market, by Country, 2022 Vs 2030 (in%)

13.6.2. U.S.

13.6.3. Canada

13.6.4. Mexico

14. Europe Specialty Generics Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Europe Specialty Generics Market, by Drug Class, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Europe Specialty Generics Market, by Route of Administration, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Europe Specialty Generics Market, by Disease Area, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Europe Specialty Generics Market, by End-Users, 2017-2030(US$ Mn)

14.5.1. Overview

14.5.2. SRC Analysis

14.6. Europe Specialty Generics Market, by Country, 2017-2030 (US$ Mn)

14.6.1. Europe Specialty Generics Market, by Country, 2022 Vs 2030 (in%)

14.6.2. UK

14.6.3. France

14.6.4. Germany

14.6.5. Italy

14.6.6. Spain

14.6.7. Benelux

14.6.8. Russia

14.6.9. Rest of Europe

15. Asia Pacific Specialty Generics Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Asia Pacific Specialty Generics Market, by Drug Class, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Asia Pacific Specialty Generics Market, by Route of Administration, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Asia Pacific Specialty Generics Market, by Disease Area, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Asia Pacific Specialty Generics Market, by End-Users, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. Asia Pacific Specialty Generics Market, by Country, 2017-2030 (US$ Mn)

15.6.1. Asia Pacific Specialty Generics Market, by Country, 2022 Vs 2030 (in%)

15.6.2. China

15.6.3. Japan

15.6.4. India

15.6.5. South Korea

15.6.6. South East Asia

15.6.7. Rest of Asia Pacific

16. Latin America Specialty Generics Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Latin America Specialty Generics Market, by Drug Class, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Latin America Specialty Generics Market, by Route of Administration, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Latin America Specialty Generics Market, by Disease Area, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Latin America Specialty Generics Market, by End-Users, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Latin America Specialty Generics Market, by Country, 2017-2030 (US$ Mn)

16.6.1. Latin America Specialty Generics Market, by Country, 2022 Vs 2030 (in%)

16.6.2. Brazil

16.6.3. Argentina

16.6.4. Rest of Latin America

17. Middle East Specialty Generics Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Middle East Specialty Generics Market, by Drug Class, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Middle East Specialty Generics Market, by Route of Administration, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Middle East Specialty Generics Market, by Disease Area, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Middle East Specialty Generics Market, by End-Users, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Middle East Specialty Generics Market, by Country, 2017-2030 (US$ Mn)

17.6.1. Middle East Specialty Generics Market, by Country, 2022 Vs 2030 (in%)

17.6.2. UAE

17.6.3. Saudi Arabia

17.6.4. Rest of Middle East

18. Africa Specialty Generics Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Africa Specialty Generics Market, by Drug Class, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Africa Specialty Generics Market, by Route of Administration, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Africa Specialty Generics Market, by Disease Area, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Africa Specialty Generics Market, by End-Users, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Africa Specialty Generics Market, by Country, 2017-2030 (US$ Mn)

18.6.1. Middle East Specialty Generics Market, by Country, 2022 Vs 2030 (in%)

18.6.2. South Africa

18.6.3. Egypt

18.6.4. Rest of Africa

19. Company Profiles

19.1. Teva Pharmaceuticals Industries Ltd

19.1.1. Company Overview

19.1.2. Products/Services Portfolio

19.1.3. Geographical Presence

19.1.4. SWOT Analysis

19.1.5. Financial Summary

19.1.5.1. Market Revenue and Net Profit (2019-2022)

19.1.5.2. Business Segment Revenue Analysis

19.1.5.3. Geographical Revenue Analysis

19.2. Novartis AG

19.3. Bausch Health Companies Inc

19.4. Endo Pharmaceuticals Inc

19.5. Viatris Inc

19.6. Fresenius Kabi Brasil Ltd

19.7. STADA Arzneimittel AG

19.8. Apotex Corp.

19.9. Hikma Pharmaceuticals PLC

19.10. Dr. Reddy’s Laboratories Ltd

19.11. Sun Pharmaceutical Industries Ltd

19.12. Others

20. Research Methodology

20.1. Research Methodology

20.2. Phase I – Secondary Research

20.3. Phase II – Data Modelling

20.3.1. Company Share Analysis Model

20.3.2. Revenue Based Modelling

20.4. Phase III – Primary Research

20.5. Research Limitations

20.5.1. Assumptions

List of Figures

FIG. 1 Global Specialty Generics Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Specialty Generics Market Segmentation

FIG. 4 Global Specialty Generics Market, by Drug Class, 2022 (US$ Mn)

FIG. 5 Global Specialty Generics Market, by Route of Administration, 2022 (US$ Mn)

FIG. 6 Global Specialty Generics Market, by Disease Area, 2022 (US$ Mn)

FIG. 7 Global Specialty Generics Market, by End-Users, 2022 (US$ Mn)

FIG. 8 Global Specialty Generics Market, by Geography, 2022 (US$ Mn)

FIG. 9 Attractive Investment Proposition, by Drug Class, 2022

FIG. 10 Attractive Investment Proposition, by Route of Administration, 2022

FIG. 11 Attractive Investment Proposition, by Disease Area, 2022

FIG. 12 Attractive Investment Proposition, by End-Users, 2022

FIG. 13 Attractive Investment Proposition, by Geography, 2022

FIG. 14 Global Market Share Analysis of Key Specialty Generics Market Manufacturers, 2022

FIG. 15 Global Market Positioning of Key Specialty Generics Market Manufacturers, 2022

FIG. 16 Global Specialty Generics Market Value Contribution, By Drug Class, 2022 & 2030 (Value %)

FIG. 17 Global Specialty Generics Market, by Oncology Drugs, Value, 2017-2030 (US$ Mn)

FIG. 18 Global Specialty Generics Market, by Injectable Drugs, Value, 2017-2030 (US$ Mn)

FIG. 19 Global Specialty Generics Market, by Biologics, Value, 2017-2030 (US$ Mn)

FIG. 20 Global Specialty Generics Market, by Complex Formulations, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Specialty Generics Market, by Respiratory Drugs, Value, 2017-2030 (US$ Mn)

FIG. 22 Global Specialty Generics Market, by Dermatology Drugs, Value, 2017-2030 (US$ Mn)

FIG. 23 Global Specialty Generics Market, by Ophthalmology Drugs, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Specialty Generics Market, by Others, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Specialty Generics Market Value Contribution, By Route of Administration, 2022 & 2030 (Value %)

FIG. 26 Global Specialty Generics Market, by Oral, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Specialty Generics Market, by Injectable, Value, 2017-2030 (US$ Mn)

FIG. 28 Global Specialty Generics Market, by Topical, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Specialty Generics Market, by Ocular, Value, 2017-2030 (US$ Mn)

FIG. 30 Global Specialty Generics Market, by Inhalable, Value, 2017-2030 (US$ Mn)

FIG. 31 Global Specialty Generics Market Value Contribution, By Disease Area, 2022 & 2030 (Value %)

FIG. 32 Global Specialty Generics Market, by Cancer, Value, 2017-2030 (US$ Mn)

FIG. 33 Global Specialty Generics Market, by Autoimmune Diseases, Value, 2017-2030 (US$ Mn)

FIG. 34 Global Specialty Generics Market, by Respiratory Diseases, Value, 2017-2030 (US$ Mn)

FIG. 35 Global Specialty Generics Market, by Dermatological Conditions, Value, 2017-2030 (US$ Mn)

FIG. 36 Global Specialty Generics Market, by Ophthalmic Disorders, Value, 2017-2030 (US$ Mn)

FIG. 37 Global Specialty Generics Market, by Others, Value, 2017-2030 (US$ Mn)

FIG. 38 Global Specialty Generics Market Value Contribution, By End-Users, 2022 & 2030 (Value %)

FIG. 39 Global Specialty Generics Market, by Hospitals and Clinics, Value, 2017-2030 (US$ Mn)

FIG. 40 Global Specialty Generics Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 41 Global Specialty Generics Market, by Specialty Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 42 Global Specialty Generics Market, by Online Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 43 North America Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 44 U.S. Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 45 Canada Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 46 Mexico Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 47 Europe Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 48 Germany Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 49 France Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 50 U.K. Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 51 Italy Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 52 Spain Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 53 Benelux Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 54 Russia Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 55 Rest of Europe Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 56 Asia Pacific Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 57 China Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 58 Japan Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 59 India Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 60 South Korea Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 61 South-East Asia Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 62 Rest of Asia Pacific Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 63 Latin America Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 64 Brazil Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 65 Argentina Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 66 Rest of Latin America Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 67 Middle East Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 68 UAE Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 69 Saudi Arabia Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 70 Rest of Middle East Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 71 Africa Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 72 South Africa Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 73 Egypt Specialty Generics Market, 2017-2030 (US$ Mn)

FIG. 74 Rest of Africa Specialty Generics Market, 2017-2030 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Specialty Generics Market

TABLE 2 Global Specialty Generics Market: Market Drivers Impact Analysis

TABLE 3 Global Specialty Generics Market: Market Restraints Impact Analysis

TABLE 4 Global Specialty Generics Market, by Competitive Benchmarking, 2022

TABLE 5 Global Specialty Generics Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Specialty Generics Market, by Key Strategies Analysis, 2022

TABLE 7 Global Specialty Generics Market, by Oncology Drugs, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Specialty Generics Market, by Oncology Drugs, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Specialty Generics Market, by Injectable Drugs, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Specialty Generics Market, by Injectable Drugs, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Specialty Generics Market, by Biologics, By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Specialty Generics Market, by Biologics, By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Specialty Generics Market, by Complex Formulations, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Specialty Generics Market, by Complex Formulations, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Specialty Generics Market, by Respiratory Drugs, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Specialty Generics Market, by Respiratory Drugs, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Specialty Generics Market, by Dermatology Drugs, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Specialty Generics Market, by Dermatology Drugs, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Specialty Generics Market, by Ophthalmology Drugs, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Specialty Generics Market, by Ophthalmology Drugs, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Specialty Generics Market, by Others, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Specialty Generics Market, by Others, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Specialty Generics Market, by Oral, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Specialty Generics Market, by Oral, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Specialty Generics Market, by Injectable, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Specialty Generics Market, by Injectable, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Specialty Generics Market, by Topical, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Specialty Generics Market, by Topical, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Specialty Generics Market, by Ocular, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Specialty Generics Market, by Ocular, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Specialty Generics Market, by Inhalable, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Specialty Generics Market, by Inhalable, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Specialty Generics Market, by Cancer, By Region, 2017-2022 (US$ Mn)

TABLE 34 Global Specialty Generics Market, by Cancer, By Region, 2023-2030 (US$ Mn)

TABLE 35 Global Specialty Generics Market, by Autoimmune Diseases, By Region, 2017-2022 (US$ Mn)

TABLE 36 Global Specialty Generics Market, by Autoimmune Diseases, By Region, 2023-2030 (US$ Mn)

TABLE 37 Global Specialty Generics Market, by Respiratory Diseases, By Region, 2017-2022 (US$ Mn)

TABLE 38 Global Specialty Generics Market, by Respiratory Diseases, By Region, 2023-2030 (US$ Mn)

TABLE 39 Global Specialty Generics Market, by Dermatological Conditions, By Region, 2017-2022 (US$ Mn)

TABLE 40 Global Specialty Generics Market, by Dermatological Conditions, By Region, 2023-2030 (US$ Mn)

TABLE 41 Global Specialty Generics Market, by Ophthalmic Disorders, By Region, 2017-2022 (US$ Mn)

TABLE 42 Global Specialty Generics Market, by Ophthalmic Disorders, By Region, 2023-2030 (US$ Mn)

TABLE 43 Global Specialty Generics Market, by Others, By Region, 2017-2022 (US$ Mn)

TABLE 44 Global Specialty Generics Market, by Others, By Region, 2023-2030 (US$ Mn)

TABLE 45 Global Specialty Generics Market, by Hospitals and Clinics, By Region, 2017-2022 (US$ Mn)

TABLE 46 Global Specialty Generics Market, by Hospitals and Clinics, By Region, 2023-2030 (US$ Mn)

TABLE 47 Global Specialty Generics Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 48 Global Specialty Generics Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 49 Global Specialty Generics Market, by Specialty Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 50 Global Specialty Generics Market, by Specialty Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 51 Global Specialty Generics Market, by Online Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 52 Global Specialty Generics Market, by Online Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 53 Global Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 54 Global Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 55 Global Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 56 Global Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 57 Global Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 58 Global Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 59 Global Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 60 Global Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 61 Global Specialty Generics Market, by Region, 2017-2022 (US$ Mn)

TABLE 62 Global Specialty Generics Market, by Region, 2023-2030 (US$ Mn)

TABLE 63 North America Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 64 North America Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 65 North America Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 66 North America Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 67 North America Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 68 North America Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 69 North America Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 70 North America Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 71 North America Specialty Generics Market, by Country, 2017-2022 (US$ Mn)

TABLE 72 North America Specialty Generics Market, by Country, 2023-2030 (US$ Mn)

TABLE 73 United States Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 74 United States Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 75 United States Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 76 United States Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 77 United States Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 78 United States Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 79 United States Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 80 United States Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 81 Canada Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 82 Canada Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 83 Canada Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 84 Canada Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 85 Canada Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 86 Canada Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 87 Canada Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 88 Canada Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 89 Mexico Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 90 Mexico Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 91 Mexico Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 92 Mexico Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 93 Mexico Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 94 Mexico Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 95 Mexico Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 96 Mexico Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 97 Europe Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 98 Europe Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 99 Europe Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 100 Europe Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 101 Europe Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 102 Europe Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 103 Europe Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 104 Europe Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 105 Europe Specialty Generics Market, by Country, 2017-2022 (US$ Mn)

TABLE 106 Europe Specialty Generics Market, by Country, 2023-2030 (US$ Mn)

TABLE 107 Germany Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 108 Germany Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 109 Germany Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 110 Germany Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 111 Germany Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 112 Germany Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 113 Germany Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 114 Germany Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 115 France Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 116 France Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 117 France Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 118 France Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 119 France Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 120 France Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 121 France Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 122 France Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 123 United Kingdom Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 124 United Kingdom Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 125 United Kingdom Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 126 United Kingdom Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 127 United Kingdom Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 128 United Kingdom Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 129 United Kingdom Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 130 United Kingdom Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 131 Italy Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 132 Italy Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 133 Italy Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 134 Italy Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 135 Italy Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 136 Italy Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 137 Italy Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 138 Italy Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 139 Spain Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 140 Spain Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 141 Spain Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 142 Spain Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 143 Spain Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 144 Spain Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 145 Spain Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 146 Spain Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 147 Benelux Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 148 Benelux Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 149 Benelux Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 150 Benelux Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 151 Benelux Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 152 Benelux Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 153 Benelux Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 154 Benelux Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 155 Russia Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 156 Russia Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 157 Russia Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 158 Russia Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 159 Russia Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 160 Russia Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 161 Russia Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 162 Russia Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 163 Rest of Europe Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 164 Rest of Europe Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 165 Rest of Europe Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 166 Rest of Europe Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 167 Rest of Europe Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 168 Rest of Europe Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 169 Rest of Europe Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 170 Rest of Europe Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 171 Asia Pacific Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 172 Asia Pacific Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 173 Asia Pacific Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 174 Asia Pacific Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 175 Asia Pacific Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 176 Asia Pacific Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 177 Asia Pacific Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 178 Asia Pacific Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 179 China Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 180 China Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 181 China Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 182 China Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 183 China Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 184 China Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 185 China Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 186 China Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 187 Japan Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 188 Japan Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 189 Japan Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 190 Japan Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 191 Japan Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 192 Japan Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 193 Japan Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 194 Japan Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 195 India Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 196 India Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 197 India Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 198 India Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 199 India Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 200 India Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 201 India Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 202 India Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 203 South Korea Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 204 South Korea Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 205 South Korea Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 206 South Korea Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 207 South Korea Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 208 South Korea Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 209 South Korea Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 210 South Korea Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 211 South-East Asia Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 212 South-East Asia Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 213 South-East Asia Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 214 South-East Asia Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 215 South-East Asia Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 216 South-East Asia Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 217 South-East Asia Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 218 South-East Asia Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 219 Rest of Asia Pacific Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 220 Rest of Asia Pacific Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 221 Rest of Asia Pacific Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 222 Rest of Asia Pacific Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 223 Rest of Asia Pacific Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 224 Rest of Asia Pacific Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 225 Rest of Asia Pacific Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 226 Rest of Asia Pacific Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 227 Latin America Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 228 Latin America Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 229 Latin America Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 230 Latin America Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 231 Latin America Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 232 Latin America Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 233 Latin America Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 234 Latin America Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 235 Brazil Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 236 Brazil Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 237 Brazil Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 238 Brazil Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 239 Brazil Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 240 Brazil Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 241 Brazil Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 242 Brazil Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 243 Argentina Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 244 Argentina Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 245 Argentina Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 246 Argentina Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 247 Argentina Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 248 Argentina Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 249 Argentina Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 250 Argentina Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 251 Rest of Latin America Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 252 Rest of Latin America Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 253 Rest of Latin America Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 254 Rest of Latin America Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 255 Rest of Latin America Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 256 Rest of Latin America Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 257 Rest of Latin America Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 258 Rest of Latin America Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 259 Middle East Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 260 Middle East Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 261 Middle East Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 262 Middle East Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 263 Middle East Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 264 Middle East Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 265 Middle East Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 266 Middle East Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 267 UAE Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 268 UAE Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 269 UAE Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 270 UAE Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 271 UAE Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 272 UAE Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 273 UAE Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 274 UAE Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 275 Saudi Arabia Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 276 Saudi Arabia Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 277 Saudi Arabia Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 278 Saudi Arabia Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 279 Saudi Arabia Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 280 Saudi Arabia Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 281 Saudi Arabia Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 282 Saudi Arabia Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 283 Rest of Middle East Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 284 Rest of Middle East Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 285 Rest of Middle East Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 286 Rest of Middle East Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 287 Rest of Middle East Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 288 Rest of Middle East Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 289 Rest of Middle East Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 290 Rest of Middle East Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 291 Africa Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 292 Africa Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 293 Africa Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 294 Africa Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 295 Africa Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 296 Africa Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 297 Africa Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 298 Africa Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 299 South Africa Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 300 South Africa Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 301 South Africa Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 302 South Africa Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 303 South Africa Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 304 South Africa Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 305 South Africa Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 306 South Africa Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 307 Egypt Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 308 Egypt Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 309 Egypt Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 310 Egypt Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 311 Egypt Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 312 Egypt Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 313 Egypt Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 314 Egypt Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

TABLE 315 Rest of Africa Specialty Generics Market, by Drug Class, 2017-2022 (US$ Mn)

TABLE 316 Rest of Africa Specialty Generics Market, by Drug Class, 2023-2030 (US$ Mn)

TABLE 317 Rest of Africa Specialty Generics Market, by Route of Administration, 2017-2022 (US$ Mn)

TABLE 318 Rest of Africa Specialty Generics Market, by Route of Administration, 2023-2030 (US$ Mn)

TABLE 319 Rest of Africa Specialty Generics Market, by Disease Area, 2017-2022 (US$ Mn)

TABLE 320 Rest of Africa Specialty Generics Market, by Disease Area, 2023-2030 (US$ Mn)

TABLE 321 Rest of Africa Specialty Generics Market, by End-Users, 2017-2022 (US$ Mn)

TABLE 322 Rest of Africa Specialty Generics Market, by End-Users, 2023-2030 (US$ Mn)

Frequently Asked Questions

What is the current size of the global specialty generics market?

The global specialty generics market was valued at USD 69158.6 Million in 2022.

What is the expected growth rate of the specialty generics market between 2023 and 2030?

The specialty generics market is expected to grow at a CAGR of 10.3% between 2023 and 2030, reaching USD 151513.1 Million in 2030.

Which segment is leading the market share in terms of drug class?

Injectable drugs are the leading segment by drug class, holding over 30% share in value in 2022.

Which route of administration segment governs the global demand for specialty generics?

The injectable segment governs the global demand for specialty generics, holding a massive market share of over 28% in 2022.

Which disease area segment will post the highest CAGR in the forecast period?

The cancer and respiratory diseases segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the specialty generics industry?

North America is driving the rapid growth of the specialized generics industry, accounting for more than one-third of its market share in 2022.

Who are the major players in the global specialty generics market?

The top players include Teva Pharmaceuticals Industries Ltd, Novartis AG, Bausch Health Companies Inc, Endo Pharmaceuticals Inc, Viatris Inc, Fresenius Kabi Brasil Ltd, Apotex Corp., STADA Arzneimittel AG, Dr. Reddy’s Laboratories Ltd, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd, and Others.

What are the major market drivers of the specialty generics industry?

Major market drivers are the increasing demand for cost-effective medications, growth in biosimilars, advancements in biopharmaceuticals, rising prevalence of chronic diseases, and expanding access to healthcare.

What are the major market restraints of the specialty generics industry?

Major market restraints of the specialty generics industry include stringent regulatory requirements and approval processes, intellectual property challenges and legal disputes, supply chain complexities, price competition, and the high cost of research and development for complex formulations.

What are the major market opportunities of the specialty generics industry?

Major market opportunities in the specialty generics industry include expanding into emerging markets, focusing on rare diseases and orphan drugs, leveraging data analytics for informed decision-making, developing innovative drug delivery systems, and capitalizing on the global trend of personalized therapies.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –